12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

UCB, Astellas sales and marketing update

UCB and partner Astellas launched Cimzia certolizumab pegol in Japan to treat rheumatoid arthritis in adults who have an inadequate response to conventional treatment....

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >